Glycogen storage disease type 1b (GSD-1b) (OMIM 232220) is an autosomal recessive disorder that was first distinguished as a separate entity in 1978 [1] . GSD-1b is caused by a mutation in the glucose-6-phosphate transporter 1 gene (G6PT1) located on chromosome 11q23 [2, 3] . This transporter is important in translocating the glucose-6-phosphate (G6P) from the cytoplasm across the endoplasmic reticulum (ER) where distinctive enzymes, depending on the cell type, hydrolyze this compound [4] . Glucose-6-phosphatase-α (G6Pase-α) that is strictly expressed and embedded in the ER of the liver, kidney, and intestines hydrolyzes G6P to glucose, an essential component of glucose homeostasis between meals [4] . Its deficiency leads to GSD type 1a [5] . Glucose-6-phosphatase-β (G6Pase-β) is another enzyme that is expressed ubiquitously in cells with increased glucose demands including neutrophils [6, 7] . Failure to meet these demands results in stressed ER and ultimately apoptosis of neutrophils [8] . Therefore, G6PT1 mutation results in defective translocation of G6P in all of the above-mentioned cell types and in addition to the GSD-1a phenotype, the majority of patients with GSD-1b develop neutropenia, neutrophil dysfunction, recurrent infections, and inflammatory bowel disease (IBD) [9, 10] . Dietary modifications, granulocytes colonystimulating factor (G-CSF), and liver transplant are the main management strategies [11] . While G-CSF has been used successfully to improve neutrophil counts and decrease recurrent infections, it has not been shown to decrease apoptosis or improve chemotaxis [8, 12] . Besides, G-CSF has its own risks including splenomegaly with hypersplenism, osteoporosis/osteopenia, and leukemic transformation [13, 14] . Liver transplant can restore glucose homeostasis for GSD-1a but cannot resolve the neutropenia component in GSD-1b. Hematopoietic cell transplant (HCT) from a matched related donor has been reported in one patient for extremely poor quality of life despite maximal therapy as evidenced by frequent hospital stays and life-threatening complications caused by impaired bone marrow function [15] . Post-transplant course in that patient was notable for improved neutrophil counts, decreased infections, improved metabolic control, and the original plan for liver transplant was postponed indefinitely [15] .
Our patient is a 5-year-old Hispanic male born to consanguineous parents, who presented at 4 months of age with abdominal distension and vomiting. He had hepatosplenomegaly, mild neutropenia >1 × 10 9 /L, blood glucose of 20 mg/dL, transaminitis, lactic acidosis, and hypertriglyceridemia. Gastrostomy tube (G-tube) was placed and continuous feeds were initiated after initial unsuccessful attempts at daytime bolus feeding. Liver biopsy showed glycogenosis with micro and macro-vesicular steatosis. GSD in the liver was significant for low G6P activity ( Table 1) . Analysis of the G6PT1 gene, SLC37A4 sequence, revealed a novel homozygous mutation at c.170C>A (p.S57X) predicted to result in a stop codon and thus, a deleterious mutation, consistent with GSD-1b. His neutropenia gradually worsened and he eventually developed severe neutropenia.
Over the course of 3 years from the time of diagnosis to HCT, cumulative hospital length of stay (LOS) was 215 days with 98 emergency room visits, in 54 of which the patient was admitted, and five of the admissions were to pediatric intensive care unit. Admissions were for recurrent hypoglycemia despite continuous feeds, hypoglycemic seizures, G-tube or NJ tube disconnection, dislocation or malfunction, prolonged healing of the G-tube stoma after Gtube removal, neutropenic fevers, and infections. Infections were particularly for cellulitis around G-tube, E.coli urinary tract infection with resultant pyelonephritis and septic shock, fungal skin and nail infections, recurrent Clostridium difficile gastroenteritis and colitis, methicillin-sensitive Staphylococcus aureus bacteremia, disseminated herpes simplex virus DNAemia, mastoiditis, bronchiolitis, recurrent viral upper respiratory tract infections, and E. coli gastroenteritis.
He was started on granulocyte colony-stimulating factor (G-CSF) at 6 months of age for severe neutropenia. Initial dose was 4 mcg/kg daily and was gradually increased over time to 6.5 mcg/kg daily, however, he continued to have intermittent neutropenia. Bone marrow aspiration showed hypercellular myelopoiesis, increased megakaryocytes and no evidence of malignancy. He developed hypothyroidism as a manifestation of his primary disease and was noted to have developmental delay. On two occasions prior to transplant, patient presented with loose watery stools, abdominal pain and distention, and esophagogastroduodenoscopy showed reactive gastritis without inflammatory bowel. Additionally, abdominal computed tomography scan showed thickening concerning for colitis in the descending, sigmoid colon, and rectum. Due to refractory neutropenia causing recurrent infections, especially infectious colitis, severe metabolic control and poor quality of life, the decision was made to proceed with HCT. We postulated that transplant will cure his neutropenia, thereby decreasing the risk of infections and improve his quality of life; however, it was unlikely to have any direct effect on the metabolic component of GSD-1b.
At 3.5 years of age, he underwent a 9/10 HLA-matched unrelated bone marrow transplant with reduced conditioning regimen of fludarabine (150 mg/m 2 ), melphalan (140 mg/m 2 ), and intermediate schedule alemtuzumab (1 mg/kg divided in three doses). Tacrolimus and mycophenolate mofetil were given for graft vs. host disease (GvHD) prophylaxis. G-CSF was started on day +1 and continued until neutrophil engraftment was achieved on day 16. Sorted chimerisms obtained at 1, 2, 3, 6, 12, and 24 months posttransplant showed 99% donor in all subsets. Post-transplant course was complicated by grade 3 aGvHD (skin stage 2 and gut stage 1) that responded to systemic steroids, beclomethasone, and topical steroids. He had multiple recurrences of skin GvHD on day +45 (stage 3), day +145, day +254 and +16 months (stage 1). Other complications included adenoviremia/adenovirus colitis, cytomegaloviru, ebstein-barr virus, human herpesvirus 6 reactivations, severe hypertension, in addition to pneumatosis intestinalis secondary to steroids for acute GvHD. His viremias resolved spontaneously without medical intervention except for cytomegaloviru viremia that was treated pre-emptively with ganciclovir, and no cytomegaloviru-associated complications have developed. He was on continuous feeds through jejunostomy tube with a plan to switch to bolus feeds in the long term. His hepatosplenomegaly resolved by 9 months after HCT.
The neutropenia was corrected after HCT and his quality of life also improved (Table 2) . For the 2 years that followed his transplant, he had only seven emergency room visits, was admitted on five of those visits (once for fever in the setting of central line and RSV infection, once for E.coli septic shock, twice for hypoglycemic seizures secondary to Glucose-6-phosphatase (mmol/min/g tissue) 2.5 3.50 ± 0.8
Liver glycogen content tested in the normal range with normal structure. Enzymes' activities showed normal to low normal ranges Number of visits, admissions, and hospital stay was totaled over the 3 years period prior to transplant and the 2 years post-HSCT ER emergency visits, HLOS total hospital length of stay in days, PICU pediatric intensive care unit a Patient had two febrile episodes post-transplant where ANC nadir was 650 cells/uL and 704 cells/uL. Improved metabolic control is mainly reflected by decreased hypoglycemic episodes and the resultant urgent visits/admissions, while less observed in the laboratory values, which were mainly obtained for our patient during an illness or acute event J-tube dysfunction, and once for finger cellulitis). The other two emergency room visits were for symptomatic hypoglycemia with J-tube malfunction. His cumulative LOS was only 32 days (compared to 215 days pre-transplant), 18 days of which were for the E.coli septic shock admission. On his last follow-up in the BMT clinic, he was reported to be enjoying school and its activities, developing well except for speech delay. He was still on continuous feeds via the G-tube. Unfortunately, at 25 months posttransplant he had status epilepticus secondary to prolonged hypoglycemia from feeding tube disconnection at night time leading to extensive metabolic/ischemic stroke affecting bilateral cortices and basal ganglia resulting in severe neurological deficits. Our review of the literature revealed only one report of successful maternal fully human leukocyte antigen-matched peripheral blood HCT for GSD-1b in England using reduced toxicity conditioning regimen [15] . In summary, our case shows that reduced-intensity unrelated bone marrow transplant in GSD-1b corrects the neutropenia, thereby decreasing the recurrent infections, indirectly improving metabolic control and achieving better quality of life.
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